Abstract
A great deal of knowledge about anterior pituitary development, the pathogenesis of pituitary tumor and pituitary tumor progression has accumulated during the past decade. The role of multiple genes and gene products in pituitary development and the relationship of these genes to postnatal pituitary function and pituitary tumor development are being actively explored.
Recent studies indicate that genes important in pituitary development do not contribute to pituitary tumorigenesis. However, mutations and other genetic alterations in these genes often lead to pituitary hypofunction. Many oncogenes and tumor suppressor genes that contribute to pituitary tumorigenesis have been described. There is a growing body of evidence showing that cellular and molecular changes in cyclins and cyclin-dependent kinase inhibitors contribute to pituitary tumorigenesis. Finally, recent comparative genomic hybridization studies show that many more genes that are important in pituitary tumorigenesis and tumor progression have yet to bebreak discovered.
Similar content being viewed by others
References
Treier M, Gleiberman AS, O'Connell SM, Szeto DP, McMahon JA, McMahon AP, Rosenfeld MG: Multistep signaling requirements for pituitary organogenesis in vivo. Genes Dev 12: 1691–1704, 1998
Asa SL, Ezzat S: The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19: 798–827, 1998
Farrell WE, Clayton RN: Molecular pathogenesis of pituitary tumors. Frontiers Neuroendocrinol 21: 174–198, 2000
Heaney AP, Melmed S: New pituitary oncogenes. Endocrine-Related Cancer 7: 3–15, 2000
Burrows H, Douglas K, Seasholtz A, Camper S: Geneology of anterior pituitary gland: tracing a family tree. Trends Endocrinol Metab 10: 343–352, 1999
Tremblay JJ, Lanctot C, Drouin J: The pan-pituitary activator of transcription factor Ptx1 (pituitary homeobox) acts in synergy with SF-1 and Pit-1 and is an upstream regulator of the Lim-homeodomain gene Lim3/Lhx3. Mol Endocrinol 12: 428–441, 1998
Gage PJ, Camper SA: Pituitary homeobox 2, a novel member of the bicoid-related family of homeobox genes is a potential regulator of anterior structure formation. Hum Mol Genet 6: 457–464, 1997
Kurotani R, Tahara S, Sanno N, Teramoto A, Mellon PL, Inoue K, Yoshimura S, Osamura RY: Expression of Ptx1 in the adult rat pituitary glands and pituitary cell lines: hormone-secreting cells and folliculo-stellate cells. Cell Tissue Res 298: 55–61, 1999
Gage PJ, Brinkmeier ML, Scarlett LM, Knapp LT, Camper SA, Mahon KA: The Ames dwarf gene df is required early in pituitary ontogeny for the extinction of Rpx transcription and initiation of lineage-specific cell proliferation. Mol Endocrinol 10: 1570–1581, 1996
Pfäffle RW, DiMattia GE, Parks JS, Brown MR, Wit JM, Jansen M, van der Nat H, van den Brande JL, Rosenfeld MG, Ingraham HA: Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science 257: 1118–1121, 1992
Nakamura Y, Usui T, Mizuta H, Murabe H, Muro S, Suda M, Tanaka K, Tanaka I, Shimatsu A, Nakao K: Characterization of prophet of pit-1 gene expression in normal pituitary and pituitary adenomas in human. J Clin Endocrinol Metab 84: 1414–1419, 1999
Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S: Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 71: 1427–1433, 1990
Alexander JM, Biller BMK, Bikkal H, Zervas NT, Arnold A, Klibanski A: Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 86: 336–340, 1990
Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, Duh OY, Clark OH, Kawasaki E, Bourne HR, McCormick F: Two G protein oncogenes in human endocrine tumors. Science 249: 655–659, 1990
Spada A, Vallar L, Faglia G:Gprotein oncogenes in pituitary tumors. Trends Endocrinol Metab 3: 355–360, 1992
Yoshimoto K, Iwahana H, Fukuda A, Sano T, Itakura M: Rare mutation of the Gs alpha-subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction - primer introduced restriction analysis. Cancer 72: 1386–1393, 1993
Yang I, Park S, Ryu M, Woo J, Kim S, Kim J, Kim Y, Choi Y: Characteristics of gsp-positive growth hormonesecreting pituitary tumors in Korean acromegalic patients. Eur J Endocrinol 134: 720–726, 1996
Berthrat J, Chanson P, Montmimy M: The cyclic adenosine 35-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocrinol 9: 777–783, 1995
Cai WY, Alexander JM, Headley-Whyte ET, Scheithauer BW, Jameson JL, Zervos NT, Klibanski A: Ras mutations in human prolactinomas and pituitary carcinomas. J Clin Endocrinol Metab 78: 89–93, 1994
Pei L, Melmed S, Scheithauer B, Kovacs K, Prager D: H-ras mutations in human pituitary carcinoma metastasis. J Clin Endocrinol Metab 78: 842–846, 1994
Karger HJ, Alexander JM, Hedley-Whyte ET, Klibansky A, Jameson LJ: Ras mutations in human pituitary tumors. J Clin Endocrinol Metab 74: 914–919, 1992
Pei L, Melmed S: Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11: 433–441, 1997
Zhang X, Horwitz GA, Heaney AP, Nakashima M, Bronotein M, Melmed S: Pituitary tumor transforming gene expression in human pituitary adenomas. J Clin Endocrinol Metab 84: 761–767, 1999
Hunter T, Pines J: Cyclins and cancer II C cyclinDandCDK inhibitors come of age. Cell 79: 573–582, 1994
Sherr CJ: Mammalian GI cyclins. Cell 73: 1059–1065, 1993
Hibberts NA, Simpson DJ, Bicknell JE, Broone JC, Hobin PR, Clayton RN, Farrell WE: Analysis of cyclin-D1 (CCND1) allelic imbalance and over-expression in sporadic pituitary tumors. Clin Cancer Res 5: 2133–2139, 1999
Jordan S, Lidher K, Korbonits M, Lowe DG, Grossman AB: Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol 143: R1–R6, 2000
Qian X, Kulig E, Jin L, Lloyd RV: Expression of D-type cyclins in normal and neoplastic rat pituitary. Endocrinology 139: 2058–2067, 1998
Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC, Doppman JL, Kim YS, Lubensky IA, Zhuang Z, Green JS, Guru SC, Manickam P, Olufemi SE, Liotta LA, Chandrasekharappa SC, Collins FS, Spiegel AM, Burns AL, Marx SJ: Germ-line mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 6: 1169–1175, 1997
Asa SL, Somers K, Ezzat S: TheMEN-1gene is rarely downregulated in pituitary adenomas. J Clin Endocrinol Metab 83: 3210–3212, 1998
Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WE, Prager D: Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors. Evidence for a chromosomal 13 tumor suppressor gene other than RB. Cancer Res 55: 644–646, 1995
Simpson DJ, Magney J, Bicknell JE, Borkan AL, McNicel AM, Clayton RN, Farrell WE: Chromosome 13q deletion mapping in pituitary tumors: infrequent loss of the retinoblastoma susceptibility gene (RB1) despite loss of RB1 protein in somatotrophinomas. Cancer Res 59: 1562–1566, 1999
Levy A, Hall S, Yendall WA, Lightman SL: p53 gene mutations in pituitary adenoma: rare events. Clin Endocrinol 41: 809–814, 1994
Herman V, Drazin NZ, Gonsky R, Melmed S: Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 77: 50–55, 1993
Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER: p53 expression in pituitary adenomas and carcinoma. Correlation with invasiveness and tumor growth fractions. Neurosurgery 38: 765–771, 1996
Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BL, Schoene WC: Pituitary carcinoma. A clinicopathologic study of 15 cases. Cancer 79: 804–812, 1997
Takino H, Herman V, Weiss M, Melmed S: Purine binding factor (nm23) gene expression in pituitary tumors: markers of adenoma invasiveness. J Clin Endocrinol Metab 80: 1733–1738, 1995
Sherr CJ: Cancer cell cycles. Science 274: 1672–1677, 1996
Reed JA, Loganzo F Jr, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW: Loss of expression of the p16/cyclindependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 55: 2713–2718, 1995
Woloschak M, Yu A, Xiao J, Post KD: Frequent loss of the p16INK4a gene product in human pituitary tumors. Cancer Res 56: 2493–2496, 1996
Woloshak M, Yu A, Post KD: Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Mol Carcinogen 19: 221–224, 1997
Simpson DJ, Bicknell JE, McNicol AM, Clayton RN, Farrell WE: Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas. Genes Chrom Cancer 24: 328–336, 1999
Frost SJ, Simpson DJ, Clayton RN, Farrell WE:Transfection of an inducible p16/CDKN2A construct mediated reversible growth inhibition and G1 arrest in the AtT 20 pituitary tumor cell line. Mol Endocrinol 13: 1801–1810, 1999
Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW: p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 54(2): 313–323, 1999
Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27kip1 deficient mice. Cell 85: 733–744, 1996
Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 85: 721–732, 1996
Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K: Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707–720, 1996
Lloyd RV, Jin L, Qian X, Kulig E: Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 150(2): 401–407, 1997
Erickson LA: p27Kip1 and other cell-cycle protein expression in normal and neoplastic endocrine tissues. Endocr Pathol 11: 109–122, 2000
Qian X, Jin L, Kulig E, Lloyd RV: DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. Am J Pathol 153(5): 1475–1482, 1998
Qian X, Jin L, Grande JP, Lloyd RV: Transforming growth factor-beta and p27 expression in pituitary cells. Endocrinology 137(7): 3051–3060, 1996
Calle-Rodrigues RD, Giannini C, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT, Stefaneanu L, Ebright AB, Abboud CF, Davis DH: Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 73(11): 1046–1052, 1998
Jin L, Qian X, Kulig E, Sanno N, Scheithauer BW, Kovacs K, Young WF Jr, Lloyd RV: Transforming growth factorbeta, transforming growth factor-beta receptor and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 151(2): 509-519, 1997
Qian X, Jin L, Lloyd, RV: Aberrant DNA methylation of cyclin D2 and p27 genes in rodent pituitary tumor cell lines correlates with specific gene expression. Endocr Pathol 11: 85–96, 2000
Jin L, Kulig E, Qian X, Scheithauer BW, Eberhardt NL, Lloyd RV: A human pituitary adenoma cell line proliferates and maintains some differentiated functions following expression of SV40 large T-antigen. Endocr Pathol 9: 169–184, 1998
Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, Clayton RN, Jenkins PJ, Monson JP, Besser GM, Lowe DG, Grossman AG: Low expression of the cell cycle inhibitor p27kip1 in normal corticotroph cells, corticotroph tumors and malignant pituitary tumors. J Clin Endocrinol Metab 84: 3823–3830, 1999
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682–685, 1995
Morisaki H, Fujimoto A, Ando A, Nagata Y, Ikeda K, Nakanishi M: Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (cdk) inhibitor by cyclin E/Cdk2. Biochem Biophy Res Commun 240: 386–390, 1997
Vlach J, Hennrecke S, Amati B: Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27kip1. EMBO J 16: 5334–5344, 1997
Patton E, Willems A, Tyers M: Combinatorial control in ubiquitin-dependent proteolysis: don't skp the F-box hypothesis. Trends Genet 14: 6–14, 1998
Carrano AC, Eytan E, Hershko A, Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Biol 1: 193–198, 1999
Tomoda K, Kubota Y, Kato J: Degradation of the cyclindependent kinase inhibitor p27 is instigated by Jab1. Nature 398: 160–164, 1998
Franklin DS, Godfrey VL, Lee H, Kovales GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y: CD inhibitors p18INK4C and p27kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12: 2899–2911, 1998
Franklin D, Godfrey VL, O'Brien DP, Deng C, Xiang Y: Functional collaboration between different cyclindependent kinase inhibitors suppress tumor growth with distinct tissue specificity. Mol Cell Biol 20: 6147–6158, 2000
Farrell WE, Simpson D, Bates AS, Talbot JA, Bicknell J, Clayton RN: Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas. The deleted region involves markers outside the MTS1 and MTS2 gene. Cancer Res 57: 2703–2709, 1999
Daniely M, Aviram A, Adams EF, Buchfelder M, Barkai G, Fahlbusch R, Goldman B, Friedman E: Comparative genomic hybridization analysis of nonfunctioning pituitary tumors. J Clin Endocrinol Metab 83: 1801–1805, 1998
Metzger AK, Mohapatra G, Minn YA, Bollen AW, Lamborn K, Waldman F, Wilson CB, Feuerstein BG: Multiple genetic aberrations including evidence of chromosome 11q13 rearrangement detected in pituitary adenomas by comparative genomic hybridization. J Neurosurg 90: 306–314, 1999
Hui AB, Pang JC, Ko CW, Ng HK: Detection of chromosomal imbalances in growth hormone-secreting pituitary tumors by comparative genomic hybridization. Hum Pathol 30: 1019–1023, 1999
Harada K, Nishizaki T, Ozaki S, Kubota H, Harada K, Okamura T, Ilo H, Sasaki K: Cytogenetic alterations in pituitary adenomas detected by comparative genomic hybridization. Cancer Gen Cytogen 112: 38–41, 1999
Kontogeorgos G, Kopranos N: Interphase analysis of chromosome 11 in human pituitary somatotroph adenomas by direct fluorescence in situ hybridization. Endocr Pathol 7: 203–206, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lloyd, R.V. Molecular pathology of pituitary adenomas. J Neurooncol 54, 111–119 (2001). https://doi.org/10.1023/A:1012940929072
Issue Date:
DOI: https://doi.org/10.1023/A:1012940929072